These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 1971785)

  • 21. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity.
    D'Amato RJ; Alexander GM; Schwartzman RJ; Kitt CA; Price DL; Snyder SH
    Nature; 1987 May 28-Jun 3; 327(6120):324-6. PubMed ID: 2884568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The MPTP-induced parkinsonian syndrome in the goldfish is associated with major cell destruction in the forebrain and subtle changes in the optic tectum.
    Pollard HB; Kuijpers GA; Adeyemo OM; Youdim MB; Goping G
    Exp Neurol; 1996 Nov; 142(1):170-8. PubMed ID: 8912908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the rat: characterization and age-dependent effects.
    Jarvis MF; Wagner GC
    Synapse; 1990; 5(2):104-12. PubMed ID: 2309157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic L-deprenyl does not alter the restoration of striatal dopamine in MPTP-lesioned mice.
    Wiener HL; Hashim A; Lajtha A; Sershen H
    J Neurosci Res; 1989 Jul; 23(3):326-9. PubMed ID: 2504936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neural progenitor cells are protected against MPTP by MAO-B inhibitors.
    He XJ; Uetsuka K; Nakayama H
    Neurotoxicology; 2008 Nov; 29(6):1141-6. PubMed ID: 18606181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets.
    Katzenschlager R; Jackson MJ; Rose S; Stockwell K; Tayarani-Binazir KA; Zubair M; Smith LA; Jenner P; Lees AJ
    Mov Disord; 2007 Apr; 22(5):715-9. PubMed ID: 17373723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurotoxicity studies with the monoamine oxidase B substrate 1-methyl-3-phenyl-3-pyrroline.
    Ogunrombi MO; Malan SF; Terre'Blanche G; Castagnoli K; Castagnoli N; Bergh JJ; Petzer JP
    Life Sci; 2007 Jul; 81(6):458-67. PubMed ID: 17655878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ro 16-6491: a new reversible and highly selective MAO-B inhibitor protects mice from the dopaminergic neurotoxicity of MPTP.
    Da Prada M; Kettler R; Keller HH; Bonetti EP; Imhof R
    Adv Neurol; 1987; 45():175-8. PubMed ID: 2881442
    [No Abstract]   [Full Text] [Related]  

  • 29. Primate-rodent 3H-MPTP binding differences, and biotransformation of MPTP to a reactive intermediate in vitro.
    Corsini GU; Pintus S; Bocchetta A; Piccardi MP; Del Zompo M
    J Neural Transm Suppl; 1986; 22():55-60. PubMed ID: 3097260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Intrathecal infusion of brain-derived neurotrophic factor protects nigral dopaminergic neurons from degenerative changes in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced monkey parkinsonian model].
    Takeda M
    Hokkaido Igaku Zasshi; 1995 Nov; 70(6):829-38. PubMed ID: 8582706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice.
    Rajeswari A; Sabesan M
    Inflammopharmacology; 2008 Apr; 16(2):96-9. PubMed ID: 18408903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. (-)-Deprenyl protection of 1-methyl-4 phenylpyridium ion (MPP+)-induced apoptosis independent of MAO-B inhibition.
    Le W; Jankovic J; Xie W; Kong R; Appel SH
    Neurosci Lett; 1997 Mar; 224(3):197-200. PubMed ID: 9131670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Age-dependent effects of the 2'-methyl analog of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine: prevention by inhibitors of monoamine oxidase B.
    Finnegan KT; Irwin I; Delanney LE; Langston JW
    J Pharmacol Exp Ther; 1995 May; 273(2):716-20. PubMed ID: 7752075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice.
    Boireau A; Dubédat P; Bordier F; Peny C; Miquet JM; Durand G; Meunier M; Doble A
    Neuroreport; 1994 Dec; 5(18):2657-60. PubMed ID: 7696626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study.
    Benazzouz A; Boraud T; Dubédat P; Boireau A; Stutzmann JM; Gross C
    Eur J Pharmacol; 1995 Sep; 284(3):299-307. PubMed ID: 8666012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A jejunal pouch technique in the rhesus monkey and related clinical observations.
    Miller RW; Kurlan R; Wyatt JD; Gash DM
    J Med Primatol; 1992; 21(7-8):366-70. PubMed ID: 1307755
    [No Abstract]   [Full Text] [Related]  

  • 37. MPTP, selegiline, and parkinsonism.
    Akos K
    Lancet; 1987 Jan; 1(8523):38-9. PubMed ID: 2879111
    [No Abstract]   [Full Text] [Related]  

  • 38. Proteomic profiling in MPTP monkey model for early Parkinson disease biomarker discovery.
    Lin X; Shi M; Masilamoni JG; Dator R; Movius J; Aro P; Smith Y; Zhang J
    Biochim Biophys Acta; 2015 Jul; 1854(7):779-87. PubMed ID: 25617661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys.
    Ovadia A; Zhang Z; Gash DM
    Neurobiol Aging; 1995; 16(6):931-7. PubMed ID: 8622784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deprenyl: protective vs. symptomatic effect.
    Kofman OS
    Can J Neurol Sci; 1991 Feb; 18(1):83-5. PubMed ID: 1903668
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.